I've also received many emails about Exact Sciences ( EXAS), including this one from Andre L.: "I've enjoyed your work over the years. I had a question on Exact Sciences. It originally caught my eye when Odette Galli, your former colleague, wrote about it as an alternative to colonoscopy. "It's been a long road and it looked like the Pregen-Plus test was about to be included in the Ameircan Cancer Society guidelines, which meant that the insurance companies would reimburse patients (i.e., pay Exact). Now the FDA seems to have sent a warning letter about this "device" and about some additional steps that Exact may have to jump through. What's your take on this whole situation?" A blogger/stockpicker posting on the SeekingAlpha Web site seems to be responsible for the early October run in Exact Sciences. This guy was touting the stock's potential for an "exponential increase" on speculation that the Pregen-Plus screening test for colon cancer would soon receive blessing and inclusion in the American Cancer Society's colon-cancer screening guidelines, with Medicare reimbursement to follow soon after.
Manuel E. writes: "I am from Portugal. I appreciate very much your articles, they are informative enough and your opinions are wise. Thank you. Please let me know what you think about Prana Biotechnology ( PRAN) and its drug against Alzheimer's disease." Thank you, Manuel. I left Prana out of my recent column looking at various Alzheimer's drugs in clinical trials. It was an accidental oversight on my part. The company recently announced that patient-dosing in a phase IIa study of its drug PBT-2 is finishing up, with data expected in the first quarter of 2008. I don't have an opinion on PBT-2; we'll see what the data from this trial tell us. My friend Harry Tracy, editor and publisher of the NeuroInvestment newsletter, however, isn't a big fan.
An email From Pir M.: "On Oct. 11, Hemispherx Biopharma ( HEB) announced that it had filed an NDA
John B. is mad about my